HGS Refines LymphoStat-B Lupus Trial Design After Phase II Misses Endpoints
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Human Genome Sciences believes it can move ahead with Phase III trials of its systemic lupus erythematosus therapy LymphoStat-B but will refine the clinical study design - including clinical endpoints - from that used in Phase II